What exactly changed in the VRDN analyst rating on February 26, 2026?

Jefferies maintained a **Buy** and raised its price target to **$45** on February 26, 2026. Evercore ISI maintained an **Outperform** rating and added VRDN to its TAP list the same day. Both actions reinforced positive analyst sentiment.

How should investors interpret the Jefferies $45 VRDN price target?

A **$45** target reflects Jefferies’ view of Viridian’s clinical and commercial potential. It signals upside from current levels but is conditional on trial outcomes, regulatory progress, and execution. Use it alongside fundamentals and risk appetite.

Does the VRDN analyst rating change mean immediate price movement?

Maintained positive ratings typically spur modest moves, not big swings. On February 26, 2026, VRDN rose **$0.30** and **$0.26** around each note. Larger moves usually require new data or surprises.

How does Meyka view the VRDN analyst rating and stock grade?

Meyka AI rates **VRDN B+**, reflecting relative strength versus benchmarks and analyst consensus. Meyka views maintained Buy and Outperform calls as supportive but not definitive. This grade is informational and not financial advice.

Analyst Ratings

Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026

ByHuzaifa Zahoor February 27, 2026February 27, 2026

On February 26, 2026, Jefferies maintained a Buy for Viridian Therapeutics, Inc. and raised its price target to $45, marking the lead development in recent coverage. The focus here is the VRDN analyst rating, which now shows two notable firms keeping positive stances the same day. Evercore ISI also maintained Outperform and added VRDN to its TAP list on the same date. These parallel actions suggest continued analyst conviction rather than a change in sentiment, and they matter for investors watching biotech catalysts and price momentum.